RxDoctor Payments Data

Sara Martin

Pulmonary Disease · Mountain Home, ARNPI 1861616021

Payments from drug & device makers

$2,320in general payments, 2019–2025

Across 156 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$527
  • Boehringer Ingelheim$312
  • AstraZeneca$304
  • Grifols USA, LLC$195
  • Mallinckrodt Hospital Products Inc.$148
  • Takeda Pharmaceuticals U.S.A., Inc.$143
  • plus $692 from 19 others

What the payments were for

  • Food & beverage$2,320100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,320 in reported general payments places this provider in the 35th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter146$121,611
Breo ElliptaFluticasone/Vilanterol61$29,216
Spiriva RespimatTiotropium Bromide42$28,308
SymbicortBudesonide/Formoterol Fumarate65$19,872
Advair HfaFluticasone Propion/Salmeterol16$11,445
Albuterol Sulfate HfaAlbuterol Sulfate151$5,801
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,153
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$4,446
Ventolin HfaAlbuterol Sulfate38$2,945
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,197
Azithromycin111$1,142
Montelukast Sodium107$655
Prednisone38$189
Fluticasone Propionate18$140
Omeprazole16$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$527$155,980218 claims
Boehringer IngelheimSpiriva Respimat$312$28,30842 claims
AstraZenecaSymbicort$304$19,87265 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 102 pulmonary disease providers in Arkansas.

Other pulmonary disease in Mountain Home

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →